Sponsors (4)
The bill centralizes and accelerates VA access to promising mental health therapies—potentially improving care coordination, research, workforce readiness, and infrastructure planning for veterans—while raising costs and creating risks from rushed implementation, diversion of existing services, and expanded use of therapies before robust evidence is established.
Veterans will have more coordinated, nationwide access to emerging mental health treatments (PTSD, depression) through a dedicated VA office that organizes evaluation and delivery.
VA facilities and clinicians will benefit from centralized governance and a required national strategy (with timelines and assessments), reducing inconsistent access across sites and speeding organized rollout of therapies after FDA approval.
VA clinicians and the broader workforce will get clearer guidance on capacity and training needs, enabling targeted hiring and upskilling so staff are prepared to deliver novel therapies safely.
Veterans could face health risks if the VA expands access to therapies before robust evidence or regulatory approval establishes safety and efficacy.
Existing mental health services for veterans could be disrupted if clinician time, facility space, or resources are reallocated to novel therapies, reducing access to current standard care.
Creating and operating a new VA office and implementing assessments/upgrades will likely increase federal spending, potentially raising taxpayer costs or diverting funds from other VA programs.
Based on analysis of 3 sections of legislative text.
Creates a VA Office of Novel Therapeutics and requires a national preparedness and implementation strategy for emerging mental health treatments within 180 days.
Official title: Amend title 38, United States Code, to establish within the Veterans Health Administration an Office of Novel Therapeutics, and for other purposes.
Introduced March 26, 2026 by Timothy Patrick Sheehy · Last progress March 26, 2026
Creates an Office of Novel Therapeutics inside the Veterans Health Administration and requires the VA Secretary to deliver a national preparedness and implementation strategy within 180 days to guide evaluation, research, workforce planning, facility changes, and phased rollout for emerging mental health therapies (including psychedelic-assisted treatments) once they are approved. The law is largely organizational and planning-focused — it does not itself require treatment provision or appropriate new funding, but it directs centralized governance to reduce delays and safety risks when novel therapies become available.